Gator SCALES-WHF Trial Reported Heart Failure Results
Early results indicate that at-home subcutaneous furosemide was successfully used by patients in a small heart failure trial.
Updated on Oct. 11, 2026 in Heart Disease
Live Poll
Would you prefer using home-based medical devices over traditional hospital visits for managing chronic conditions?
Early results from the Gator SCALES-WHF trial involving 21 patients showed that at-home subcutaneous furosemide was successfully administered in 91% of applications. Researchers presented these findings at the HFSA Annual Scientific Meeting 2026.
Why it matters
Clinicians are testing these devices to provide sustainable therapy for patients with volume overload who have not responded to oral diuretic titration. This approach aims to manage symptoms at home while avoiding hospital readmissions.
The pilot trial included 21 participants with a mean age of 63.1 years and a median baseline left ventricular ejection fraction of 17.5%. Among the participants, 67% had heart failure with reduced ejection fraction.
The players
University of Florida
This public research university maintains a prominent medical school and health system that hosts various clinical trials for cardiovascular health.
The details
Patients in the study received the device and refill cartridges during a clinic visit to facilitate at-home decongestion using standard-of-care lab monitoring. While 92% of participants found the device easy to use, investigators recorded one device-related detachment and three total hospitalizations by day 20.
Timeline
October 9-12, 2026: Results were presented at the HFSA Annual Scientific Meeting in Phoenix, Arizona.
Day 3: Researchers recorded zero hospitalizations or emergency visits following administration.
Day 7: One patient was hospitalized following an emergency room visit.
Day 20: A total of three patients were admitted to the hospital.
30 days: This period serves as the primary outcome safety assessment for the study participants.
The Big Picture
This report on the Gator SCALES-WHF clinical trial provides an initial look at the feasibility of remote heart failure management. The findings follow a pattern set by recent shifts toward at-home monitoring to alleviate the burden on hospital resources for patients with chronic volume overload.
The study suggests that future at-home diuretic delivery may eventually offer an alternative to traditional hospital-based decongestion treatments. Participants reported high ease of use, with 67% noting symptom improvement during the pilot phase.
The takeaway
The successful use of at-home furosemide devices could eventually simplify long-term management for heart failure patients struggling with fluid retention. Patients should consult their primary cardiologist to discuss whether emerging remote monitoring technologies align with their current treatment plan.
What happens next
Researchers intend to expand the trial to a total of 100 patients and plan to implement a comparator group that receives standard oral loop diuretic escalation for comparison.
Further reading
For more information on managing chronic conditions, visit the Heart Disease section.
More information
View the full details of the Gator SCALES-WHF clinical trial information on the official registry.
Live Poll
Would you prefer using home-based medical devices over traditional hospital visits for managing chronic conditions?
